赣南医科大学学报2025，Vol.45Issue(7)：630-635,649,7.DOI:10.3969/j.issn.1001-5779.2025.07.002
肾透明细胞癌治疗进展
Advances in the treatment of clear cell renal cell carcinoma
摘要
Abstract
Clear cell renal cell carcinoma(ccRCC)is the most common subtype of renal cancer,featuring clinical characteristics such as high rates of metastasis,recurrence,and resistance to radiotherapy and chemotherapy.With its increasing incidence,ccRCC has become one of the major diseases threatening public health.Although traditional treatment methods like surgical resection,cytokine therapy,and targeted drug therapy can improve patients'prognosis to a certain extent,problems such as limited efficacy and drug resistance still exist.With the advancement of molecular biology techniques,biomarkers closely associated with ccRCC have been continuously uncovered.Among them,mutations in the Von Hippel-Lindau(VHL)gene and the consequent persistent activation of the hypoxia-inducible factor-2α(HIF-2α)pathway represent key mechanisms driving the progression of ccRCC.Belzutifan,an HIF-2α inhibitor developed based on this mechanism,has demonstrated favorable safety profiles and antitumor efficacy in clinical studies,offering novel insights into precision-targeted therapy for ccRCC.Meanwhile,nanotechnology has also shown extensive application prospects in the early diagnosis and drug delivery for ccRCC,as it can significantly enhance drug targeting,thereby improving antitumor efficacy while reducing toxic side effects.This article systematically reviews the pathogenesis,conventional therapeutic strategies,and emerging treatments of ccRCC,providing a critical foundation for optimizing clinical therapeutic regimens and guiding future research priorities.关键词
癌,肾细胞/治疗/抗药性,肿瘤/纳米技术Key words
Carcinoma,renal cell/Treatment/Drug resistance,tumors/Nanotechnology分类
医药卫生引用本文复制引用
丁涛,王晓玲..肾透明细胞癌治疗进展[J].赣南医科大学学报,2025,45(7):630-635,649,7.基金项目
江西省卫生健康委员会科技计划项目(202210862) （202210862）
